RxDoctor Payments Data

Darsit Shah, MD

Otology & Neurotology · Shrewsbury, NJNPI 1083718456

Payments from drug & device makers

$4,360in general payments, 2019–2025

Across 211 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$924
  • Sanofi$562
  • GSK$522
  • Aerin Medical Inc.$346
  • Takeda Pharmaceuticals U.S.A., Inc.$305
  • Alk-abello, Inc$263
  • plus $1K from 27 others

What the payments were for

  • Consulting fees$281%
  • Food & beverage$4,33299%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otology & neurotology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$399,515
Medicare patients
1,264
Services billed
3,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate11$8,761
Ipratropium Bromide155$5,356
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth27$3,487
Famotidine161$2,199
Azelastine Hcl61$1,985
Fluocinolone Acetonide Oil74$1,921
Omeprazole167$1,771
Amitriptyline Hcl192$1,474
Ofloxacin31$814
Fluticasone Propionate29$669
Pantoprazole Sodium35$602
Mupirocin106$594
Triamcinolone Acetonide14$251
Methylprednisolone46$251
Alprazolam37$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$240$8,76111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otology & neurotology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other otology & neurotology in Shrewsbury

Where these figures come from

Is this you, or does something look wrong? →